Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 8/20 | 0.43 |
| ▸ | DRD3 | P35462 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8256209 | 0.83 | DRD2 (0.59) | MEN1KMT2ANPC1RAB9ADRD2 | |
| SCHEMBL20313978 | 0.82 | MEN1 (0.70) | ADRA2CDDB1CRBNMEN1KMT2A | |
| SCHEMBL12362755 | 0.81 | DRD2 (0.50) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4639126 | 0.81 | PARP1 (0.51) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2234870 | 0.80 | MEN1 (0.72) | DDB1CRBNMEN1KMT2ANPC1 | |
| SCHEMBL31444802 | 0.79 | ADRA2C (0.54) | ADRA2CDDB1CRBNMEN1KMT2A | |
| SCHEMBL14632229 | 0.79 | DRD2 (0.46) | MEN1KMT2ANPC1RAB9ADRD2 | |
| SCHEMBL20313985 | 0.79 | HDAC1 (0.43) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL21349070 | 0.79 | DRD2 (0.60) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12852521 | 0.79 | CAMK1D (0.42) | MEN1KMT2ANPC1RAB9ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| EP-4245295-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4240363-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| WO-2022098806-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3793996-A1 | KINASE INHIBITORS | The University of Manchester (GB) | 2021-03-24 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1485093-A4 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050153986-A1 | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2005-07-14 | — | — | US | disclosed |
| EP-1485093-A1 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077918-A1 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003035619-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153986-A1 | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | ADRA2C 439/4885DDB1 1603/4885CRBN 2523/4885 |
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | ADRA2C 2484/4885DDB1 2521/4885CRBN 2406/4885 |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, PDXK, HIPK1 | ADRA2C 4075/4885DDB1 814/4885CRBN 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.